GATA6 Identified as a Key Factor in Pancreatic Cancer and a Potential Therapeutic Target
en-GBde-DEes-ESfr-FR

GATA6 Identified as a Key Factor in Pancreatic Cancer and a Potential Therapeutic Target

23/02/2025 Compuscript Ltd
This new review article highlights the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA). The article explores GATA6’s dual role in cancer progression and its potential as a biomarker and treatment target.

Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate of only 5%. This study finds that higher GATA6 expression correlates with better tumor differentiation and improved patient outcomes, while low GATA6 levels are linked to aggressive basal-like PDA, a chemotherapy-resistant subtype.

It is also revealed that GATA6 influences multiple cancer-related pathways—including Wnt, Notch, Hedgehog, TGF-β, and VEGFR—helping to regulate tumor development. While GATA6 overexpression can promote cancer growth, it also helps maintain epithelial differentiation, preventing tumor dedifferentiation and metastasis.

The authors suggest that GATA6 could serve as a biomarker for distinguishing PDA subtypes. Patients with low GATA6 expression are more likely to have treatment-resistant basal-like PDA, indicating a need for alternative therapies.

Notably, the findings suggest that GATA6-deficient tumors respond poorly to chemotherapy (such as FOLFIRINOX) but may benefit from targeted therapies involving the EGFR pathway. These insights could lead to more personalized treatment strategies, improving survival rates.

With pancreatic cancer accounting for 7% of all cancer-related deaths, this research advances the understanding of PDA progression and treatment response. The study underscores the need for further clinical trials to validate GATA6’s potential as a predictive biomarker and treatment target, paving the way for more effective precision medicine approaches.

Reference
Muyuan Ma, Jianhong An, Tingting Jiang, Keping Xie, GATA6 in pancreatic cancer initiation and progression, Genes & Diseases,
Volume 12, Issue 2, 2025, 101353.
DOI https://doi.org/10.1016/j.gendis.2024.101353
Journal Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

Funding Information:
Guangzhou Ruiqian Biotech Company (No. 20230330)
National Natural Science Foundation of China (No. 82072632)
Guangzhou Municipality Bureau of Science and Technology (China) (No. 202102010033)
Natural Science Foundation of Guangdong Province, China (No. 2022A1515012585)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 7.3
Impact Factor: 6.9

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )

# # # # # #
Muyuan Ma, Jianhong An, Tingting Jiang, Keping Xie, GATA6 in pancreatic cancer initiation and progression, Genes & Diseases,Volume 12, Issue 2, 2025, 101353.
https://doi.org/10.1016/j.gendis.2024.101353
Attached files
  • Image Caption: Major signaling pathways associated with GATA6 and pancreas. Wnt antagonist dickkopf1 (DKK1) is a target gene of GATA6, and GATA6 can promote the development and carcinogenesis of the pancreas by activating the Wnt pathway via repressing of DKK1. GATA6 can also regulate the pancreatic endoderm specification through hedgehog signaling by inhibiting sonic hedgehog (Shh), in company with GATA4. GATA6 is the downstream target of the transforming growth factor-β (TGF-β) pathway, and the expression changes of GATA6 can affect the differentiation of pancreatic cells and the self-renewal of pancreas progenitor. In addition, GATA6 can affect the maintenance of intestinal epithelial and goblet cell differentiation by regulating Notch signaling. GATA6 regulates the lymphatic dissemination of bladder cancer through vascular endothelial growth factor receptor (VEGFR) signaling, which may also be associated with the initiation and progression of pancreatic cancer.Image credit: The authorsImage link: https://ars.els-cdn.com/content/image/1-s2.0-S2352304224001508-gr2_lrg.jpg License type: CC BY-NC-ND
  • Image Caption: The GATA proteins with different Zinc finger domains, and the sequence comparison of GATA6 from different species. The full length of GATA1, 2, 3, 4, 5, and 6 contains the two Zinc finger domains (N-ZF and C-ZF). The sequences of GATA6 protein from human, mouse and rat are aligned together. The Zinc finger region is boxed and the N-finger and C-finger are underlined. N-ZF, N-Zinc finger domain; C-ZF, C- Zinc finger domain; H, human; M, mouse; R, rat.Image credit: The authorsImage link: https://ars.els-cdn.com/content/image/1-s2.0-S2352304224001508-gr1_lrg.jpg License type: CC BY-NC-ND
23/02/2025 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement